Tuesday evening's Ambu downgrade is obviously not good news, having made waves in the share price on Wednesday, but the medtech company's announcement really doesn't change its investment case, at least according to Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
"On the face of things it seems to be discouraging news from Ambu. Having said that, Ambu is priced on the expectations for its visualization business, and this isn't where the company has been affected by shipment delays," Løntoft Hansen says, highlighting, however, that the challenges in shipping, which cost the company DKK 75m (USD 11.7m) in the fourth quarter, will bleed into the next financial year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Former Ambu CEO's equity investments end in USD 2m losses
Juan Jose Gonzalez, who was the CEO of medtech firm Ambu until very recently, has lost just over DKK 16m (USD 2.3m) before taxes on his share purchases.
Jesper Høiland retires as chief commercial officer of Ascendis Pharma
Former executive vice president of Novo Nordisk, US, Jesper Høiland has decided to step down from his role as global chief commercial officer at Ascendis Pharma.
ALK finds replacement for long-time North America lead
Jorge Alderete, ALK’s president in North America, is leaving the firm after 23 years. He will be replaced by Hans Lindeberg, ALK’s current head of the Nordic region.
Monkeypox vaccine attracts interest for Bavarian as virus spreads
Bavarian, which signed a supply contract with an unnamed European country last week, reports it is in dialog with several countries, some yet to be affected, concerning the firm’s monkeypox vaccine.
Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis cream
Almirall is launching psoriasis cream Wynzora in Denmark. The treatment has been inlicensed from Danish firm MC2 Therapeutics, where the CEO says ”it is a special feeling” to see Wynzora launched in its home country.
Chemist for Incoming Materials in QC Department 
Cell Culture Scientist/Senior Scientist 
IRT Manager, Clinical Drug Supply 
Account Manager 
Director of Toxicology 
Key Account Manager, Europe and Asia 
Scientific Writer 
Nordic Medical Affairs Manager 
Project Manager & Scrum Master 
Clinical Trial Manager 
Industrial Designer- Design Engineer 
Director Global Engineering 
Client Talent Acquisition Specialist 
Director for innovative pre-clinical testing unit 
CMO Operations Specialist - screening & selection of CMO/CDMO’s